Estrella Immunopharma (ESLA) Projected to Release Quarterly Earnings on Wednesday

Estrella Immunopharma (NASDAQ:ESLA) is anticipated to release its results before the market opens on Wednesday, September 2nd. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

Estrella Immunopharma (NASDAQ:ESLA) last issued its earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.04. On average, analysts expect Estrella Immunopharma to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Estrella Immunopharma Stock Up 2.8%

Shares of Estrella Immunopharma stock opened at $0.72 on Tuesday. The firm’s 50 day moving average price is $0.81 and its 200-day moving average price is $1.10. Estrella Immunopharma has a 52-week low of $0.63 and a 52-week high of $3.15. The company has a market cap of $31.54 million, a P/E ratio of -3.02 and a beta of 0.88.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 25th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Institutional Investors Weigh In On Estrella Immunopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after purchasing an additional 8,318 shares during the last quarter. State Street Corp boosted its position in shares of Estrella Immunopharma by 93.5% during the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after buying an additional 20,900 shares during the period. Quadrature Capital Ltd purchased a new position in shares of Estrella Immunopharma during the fourth quarter worth $43,000. XTX Topco Ltd grew its stake in shares of Estrella Immunopharma by 376.9% in the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after buying an additional 39,099 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Estrella Immunopharma in the fourth quarter valued at $88,000. Institutional investors and hedge funds own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.